Overview

• Revenue from operations rose 9.4% year-on-year to ₹13,851 crore, driven by 13.9% growth in domestic formulations and a 16.9% jump in global specialty sales.
• Statutory net profit fell 20% to ₹2,279 crore after a $200 million US antitrust settlement and impairment charges on discontinued trials.
• Adjusted net profit, excluding exceptional items, increased 5.7% to ₹2,996 crore, underscoring resilient core earnings and margin expansion.
• Sun Pharma launched its alopecia areata drug Leqselvi in the US and is preparing for the H2 FY26 rollout of its cancer therapy Unloxcyt.
• Shares slid over 5% on investor caution and brokerages such as Dolat Capital maintained a ‘Reduce’ rating amid valuation, regulatory and margin concerns.